Clinical trials: Renal Transplant Recipient
Kidney Transplant
Low Dose Sirolimus or CsA-Based Maintenance Immunosuppression After Induction With Campath-1 in Kidney Transplantation
During the past 15 years, however, the superior immunosuppressive efficacy of CsA and the well-known toxicity of long-term steroid therapy have prompted trials of steroid withdrawal from renal allograft recipients at various…
- Trial name
- NCT00309270
- Testing
- Campath-1H
- Where
- Italy
- Volunteers
- 21 people
- Sponsor
- Mario Negri Institute for Pharmacological Research
Kidney Transplantation
REgulatory T Cell Therapy to Achieve Immunosuppression REduction
The goal of this multi-national, multi-center, open-label, randomized Phase 2 trial is to determine the safety and efficacy of administering expanded regulatory T cells (TRK-001) to prevent allograft rejection in living donor…
- Trial name
- RETIRE (NCT06552169)
- Testing
- Arm 1: SOC (mTOR + CNI), Arm 2A: TRACT/MONO mTOR, Arm 2B: TRACT/MONO CNI
- Where
- 7 sites in United States, Taiwan
- Volunteers
- 34 people
- Sponsor
- Singulera Therapeutics Inc.
Liver Transplant Recipients
L-arginine for Prevention of Kidney Damage in Liver Transplant Recipients
Chronic renal insufficiency is a common and important health problem that causes morbidity and mortality among patients who have undergone liver transplantation.
- Trial name
- NCT00587418
- Testing
- L-arginine
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Mayo Clinic
Kidney Transplantation
A Study to Assess the Safety and Efficacy of a Tacrolimus Based Immunosuppressive Regimen in Stable Kidney Transplant Recipients Converted From Cyclosporine Based Immunosuppressive Regimen
The objective of this study is to observe and evaluate the change in renal function following conversion from cyclosporine-based immunosuppressive regimen to tacrolimus-based one.
- Trial name
- NCT02963103
- Testing
- Tacrolimus
- Where
- South Korea
- Volunteers
- 13 people
- Sponsor
- Astellas Pharma Korea, Inc.
Kidney Transplant Rejection
Donor-specific Anti-HLA Antibodies Monitoring in Kidney Transplant Recipients
The aim of this study is to evaluate whether anti-HLA donor-specific antibodies monitoring can be used as an effective tool for stratification of immunological risk in Polish kidney transplant recipients.
- Trial name
- NCT03714113
- Testing
- Anti-HLA donor-specific antibodies monitoring
- Where
- Poland
- Volunteers
- 100 people
- Sponsor
- Medical University of Warsaw
Kidney Diseases
Omega-3 Fatty Acids That Affect the Immune System in Kidney Transplant Patients
The purpose of this study is to evaluate the effectiveness of nutritional supplements in increasing the amount of omega-3 fatty acids (and arginine) in the red blood cell membranes and plasma of kidney transplant patients, and…
- Trial name
- NCT00047983
- Testing
- Canola oil, Arginine, Fish oil emulsion
- Where
- 4 sites in United States
- Volunteers
- 75 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
CMV Infection, CMV
Letermovir vs Valganciclovir in CMV R+ Kidney Transplant
The purpose of this study is to find out whether letermovir can help prevent cytomegalovirus (CMV) infection in kidney transplant recipients who are CMV seropositive.
- Conditions
- CMV Infection, CMV, CMV Viremia, CMV Disease
- Trial name
- NCT07571135
- Testing
- Letermovir, Valganciclovir CMV Prophylaxis
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Elisabeth Kincaide
Post-transplant Weight Gain, Kidney Transplant
ACtive Care After Transplantation, the ACT Study
The aim of the present study is to compare the outcomes of standard care to the effects of exercise alone, and exercise combined with nutrition counseling, on post-transplantation weight gain and quality of life in renal…
- Conditions
- Post-transplant Weight Gain, Kidney Transplant, Metabolic Syndrome
- Trial name
- ACT (NCT01047410)
- Testing
- Exercise intervention, Exercise intervention and dietary advice
- Where
- 5 sites in Netherlands
- Volunteers
- 221 people
- Sponsor
- University Medical Center Groningen
Transplant Rejection
BIVV020 (SAR445088) in Prevention and Treatment of Antibody-mediated Rejection (AMR)
Primary Objectives: Cohort A: To evaluate the efficacy of BIVV020 in prevention of AMR Cohort B: To evaluate the efficacy of BIVV020 in treatment of active AMR Secondary Objectives: To assess the overall efficacy of BIVV020 in…
- Trial name
- NCT05156710
- Testing
- BIVV020 (SAR445088), Intravenous immunoglobulin (IVIg), Rituximab or biosimilar
- Where
- 27 sites in United States, Canada and 5 more
- Volunteers
- 48 people
- Sponsor
- Sanofi
Kidney Transplant Rejection
Impact of Photopheresis in the Prevention of Acute Rejection in Highly Sensitized de Novo Kidney Transplant Recipients
The aim of the present study is to evaluate the superiority of photopheresis in combination with the standard immunosuppression vs standard immunosuppression alone for the prevention of acute rejection in highly sensitized kidney…
- Trial name
- NCT04414735
- Testing
- Extracorporeal Photopheresis
- Where
- Spain
- Volunteers
- 30 people
- Sponsor
- Fundacion Clinic per a la Recerca Biomédica
Renal Disease, Renal Transplant
Comparison of Medication Adherence Between Once and Twice Daily Tacrolimus in Stable Renal Transplant Recipients
A critical aspect of real-world functioning following kidney transplantation involves how adherent individuals are to their medication regimens.
- Trial name
- NCT01334333
- Testing
- Tacrolimus - Prograf® twice daily formulation, Tacrolimus - Advagraf® once daily formulation
- Where
- Canada
- Volunteers
- 46 people
- Sponsor
- University of British Columbia
COVID-19, Renal Transplant Infection
COVID-19 Infection
Post-transplant patients with COVID-19 infection who attended Shenzhen No. 3 Hospital from December 2022 to February 2023, and enrolled the general population with COVID-19 infection who were hospitalized during the same period…
- Trial name
- NCT05926076
- Testing
- Treatment plan
- Where
- China
- Volunteers
- 610 people, healthy volunteers welcome
- Sponsor
- Tianjin First Central Hospital
Kidney Transplant, Immunosuppresion
Immunosuppression Optimization Using The Prospera Assay In Kidney Transplant Recipients (IMPAKT)
IMPAKT is a research study that looks at whether a blood test called Prospera™ can help doctors better adjust anti-rejection medications, compared to the usual way doctors manage these medications without using this test.
- Trial name
- IMPAKT (NCT07718633)
- Testing
- Prospera Immunosuppression Optimization
- Volunteers
- 750 people
- Sponsor
- Natera, Inc.
Renal Disease, Sleep Disorders
Light for Renal Transplant Recipients Having a Sleep-Wake Dysregulation
Sleep-wake dysregulation is a disturbance in the roughly 24-hour cycle of the circadian rhythm. Well known disorders presenting a sleep-wake dysregulation are seasonal affective disorder, jet lag and shift work.
- Trial name
- SleepTx-1 (NCT01256983)
- Testing
- Bright Light Therapy, Wait-list intervention
- Volunteers
- 30 people
- Sponsor
- University of Basel
Cytomegalovirus Infection, Renal Transplant Failure
Efficacy and Safety of Induction Strategies Combined With Low Tacrolimus Exposure in Kidney Transplant Recipients Receiving Everolimus or Sodium Mycophenolate
Despite the improvement of efficacy results with current immunosuppressive regimens (about 15% of incidence of acute rejection), the security schemes used do not show the same results.The most worldwide used regime is tacrolimus…
- Conditions
- Cytomegalovirus Infection, Renal Transplant Failure, Transplant; Complication, Rejection
- Trial name
- NCT01354301
- Testing
- Thymoglobulin, Everolimus, Basiliximabe
- Where
- Brazil
- Volunteers
- 300 people
- Sponsor
- Hospital do Rim e Hipertensão
Kidney Transplantation
Digital Application-Based Nursing Intervention
The purpose of this study is to evaluate the effect of a digital application-based nursing intervention on improving health outcomes among kidney transplant recipients.
- Trial name
- NCT07701057
- Testing
- Digital Application-Based Nursing Intervention
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Assiut University
Chronic Rejection, Kidney Insufficiency
Rituximab Treatment to Block HLA Antibodies in Renal Transplant Recipients
The purpose of this study is to determine if administration of rituximab blocks the development of donor specific antibodies (DSA) in transplant recipients who have developed renal dysfunction and DSA after renal transplant.
- Trial name
- NCT00261547
- Testing
- Rituximab
- Sponsor
- Massachusetts General Hospital
Kidney Transplantation
Everolimus in Combination With Cyclosporine Microemulsion in de Novo Renal Transplant Recipients
The purpose of the study in de novo renal transplant patients is to evaluate the effect on renal function of an optimized new regimen in comparison with the standard everolimus exposure plus a low-dose cyclosporine microemulsion…
- Trial name
- NCT00170885
- Testing
- Everolimus
- Where
- Switzerland
- Sponsor
- Novartis
Kidney Transplant
Planned Conversion From TAC to SRL-based Regimen in de Novo Kidney Transplant Recipients
Background Early conversion from calcineurin inhibitor to mammalian target of rapamycin inhibitor is one of the immunosuppressive strategies that have been investigated to mitigate long-term CNi associated adverse events.
- Trial name
- NCT01802268
- Testing
- Conversion from Tacrolimus to Sirolimus, Maintenance on tacrolimus
- Where
- 6 sites in Brazil
- Volunteers
- 320 people
- Sponsor
- Helio Tedesco Silva Junior
BK Viremia
BK Treatment Study
Our hypothesis is that 30 days of oral levofloxacin (FDA approved antibiotic) in patients with persistent viremia (BK virus found in blood) will impair progress to BK virus induced kidney damage by significantly decreasing or…
- Trial name
- NCT01034176
- Testing
- levofloxacin
- Where
- 8 sites in United States
- Volunteers
- 43 people
- Sponsor
- Brigham and Women's Hospital